Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration. - Wikidata - wikimedia - TriplyDB

Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration.

Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration.

http://www.wikidata.org/entity/Q35127770

about

TMC207 for treatment of people with pulmonary tuberculosis TMC207: the first compound of a new class of potent anti-tuberculosis drugs Recent advances in the diagnosis and treatment of childhood tuberculosis Bedaquiline for the treatment of multidrug-resistant tuberculosis: great promise or disappointment?Probing the interaction of the diarylquinoline TMC207 with its target mycobacterial ATP synthase Sterilizing activity of second-line regimens containing TMC207 in a murine model of tuberculosis Sterilizing Activity of Fully Oral Intermittent Regimens against Mycobacterium Ulcerans Infection in Mice Bedaquiline as part of combination therapy in adults with pulmonary multi-drug resistant tuberculosis.Ensuring the involvement of children in the evaluation of new tuberculosis treatment regimens A Review of the Evidence for Using Bedaquiline (TMC207) to Treat Multi-Drug Resistant Tuberculosis New drugs to treat multidrug-resistant tuberculosis: the case for bedaquiline Bactericidal potencies of new regimens are not predictive of their sterilizing potencies in a murine model of tuberculosis.New approaches in the diagnosis and treatment of latent tuberculosis infection Activities of TMC207, rifampin, and pyrazinamide against Mycobacterium tuberculosis infection in guinea pigs.Contribution of the nitroimidazoles PA-824 and TBA-354 to the activity of novel regimens in murine models of tuberculosis.Short-course chemotherapy with TMC207 and rifapentine in a murine model of latent tuberculosis infection.Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis Mycobacterium indicus pranii as stand-alone or adjunct immunotherapeutic in treatment of experimental animal tuberculosis.Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis Pharmacokinetics and pharmacodynamics of TMC207 and its N-desmethyl metabolite in a murine model of tuberculosis.Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline) with efavirenz in healthy volunteers: AIDS Clinical Trials Group Study A5267.Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis.Location of persisting mycobacteria in a Guinea pig model of tuberculosis revealed by r207910.Streptomycin-starved Mycobacterium tuberculosis 18b, a drug discovery tool for latent tuberculosis.Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis.New drugs and regimens for treatment of TB.Impact of the interaction of R207910 with rifampin on the treatment of tuberculosis studied in the mouse model.ATP synthase and the actions of inhibitors utilized to study its roles in human health, disease, and other scientific areas.Model-based estimates of the effects of efavirenz on bedaquiline pharmacokinetics and suggested dose adjustments for patients coinfected with HIV and tuberculosis.The Mycobacterium tuberculosis MEP (2C-methyl-d-erythritol 4-phosphate) pathway as a new drug target.Impact of fluoroquinolone resistance on bactericidal and sterilizing activity of a moxifloxacin-containing regimen in murine tuberculosis.New drugs and vaccines for drug-resistant Mycobacterium tuberculosis infections.ATP synthase inhibition of Mycobacterium avium is not bactericidal.Antimycobacterial drugs currently in Phase II clinical trials and preclinical phase for tuberculosis treatment.Bedaquiline: a novel diarylquinoline for multidrug-resistant tuberculosis.Bedaquiline for the treatment of drug-resistant tuberculosis.Diarylquinolines, synthesis pathways and quantitative structure--activity relationship studies leading to the discovery of TMC207.Prevention of drug carryover effects in studies assessing antimycobacterial efficacy of TMC207.Treatment of multidrug-resistant and extensively drug-resistant tuberculosis: current status and future prospects.Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a French cohort.

P2860

Q24199155-499B5C2E-10C0-495C-B6E3-6399F228BB59 Q24632091-FE54356E-2F8F-42CA-B7D1-31BE2E39DB84 Q26797426-EF7EEBC6-ABDB-4BF6-A77D-5292AB9F0F0C Q26824413-992A30F9-4558-4D6D-AF50-B778471B248E Q28476612-9283CA5E-9B5A-40D2-A658-72B36EFD3761 Q28477317-4EF51DC9-FAA0-48E0-87CF-08B177EECFD1 Q28552736-9C1981CC-AD4E-460F-9CD6-4886BD41DC1B Q30249515-C0077CFF-750B-42E8-AD35-8441A3D76B60 Q33361748-F95BC967-909A-4A56-8E06-A7BC64E15C8C Q33939074-8B65515D-CE62-4F1E-A52D-44866D76DBFE Q34005593-3AF9020A-B750-4C68-8C6B-C519C17CCFCC Q34290060-1253307B-0214-4939-B9B5-34F7D26D7EC4 Q34419185-1CCA6B05-8938-4860-98B0-D8803C161CC1 Q34483596-836FC190-1EDF-4183-87FC-F0CA1AFB1460 Q34922056-8EAC0560-95D5-4C3A-BD35-980E362AB2ED Q35527885-658240E2-509B-4C47-9C47-886BF7734A7B Q35598474-48A7EE80-D008-490D-BD1C-FF7E2CA06CF2 Q35646923-E2A65958-53D3-4039-900D-289384FFC497 Q35647811-2F132838-44DA-428E-BAFA-8A7B1E7A8AFF Q35806445-1703BD96-189F-41D4-B35C-407D2E5ECC96 Q35827839-541A1C97-F4D4-4CEC-A88B-8CCB20A7CEBF Q36018542-26915E6F-852C-49F8-973B-5E9A225F1C0B Q36094916-936A9BFF-75E7-4AFB-B7F3-F43FCBDDBB0C Q36364079-E3FF32CC-C927-49AA-B7CC-7BE37783C63B Q36803956-11E64A8E-23A5-4207-B0C4-E6EE1F5EA6B4 Q36825354-13B198B3-BCD3-46BB-8BC7-F8DBAE0BF58B Q36932992-13A1923F-207F-406E-8E1F-5E5F4DAFBA56 Q36995302-C1FAB8FB-50A0-4387-B0AC-1E1D0993EEAE Q37026667-6EB8E541-7C65-44F9-879E-661F8B3CBA9D Q37107614-7A469188-87AB-4291-9CEE-85B7C8AC8804 Q37124036-04EA6730-86ED-444F-A794-4419093147AC Q37150326-80097676-F0B1-4598-8B19-32E77A5ECC33 Q37409865-15DA224D-CC97-4C1D-827E-F53DE026434D Q38044744-F46B9EB3-C51E-4050-B03A-9DBB5F8D271F Q38164652-F48BF8D1-6BB7-4A0F-81C2-B09A5A7C1920 Q38386950-E481CC8E-59A5-4A14-AD48-13CDD2CB2F48 Q39712350-D3654506-56FA-47E1-84FF-366C852A7B14 Q39762794-53E7CB00-6099-405C-9360-610C86B42233 Q39967041-282DA5CC-D997-4B5E-8777-ADB4637AFE76 Q41699273-1F185EC3-49C0-4F4A-B60B-CDB402AF5D63

P2860

Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration.

http://www.wikidata.org/entity/Q35127770

description

2006 nî lūn-bûn

@nan

2006 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Combinations of R207910 with d ...... to shorten treatment duration.

@ast

Combinations of R207910 with d ...... to shorten treatment duration.

@en

type

label

Combinations of R207910 with d ...... to shorten treatment duration.

@ast

Combinations of R207910 with d ...... to shorten treatment duration.

@en

prefLabel

Combinations of R207910 with d ...... to shorten treatment duration.

@ast

Combinations of R207910 with d ...... to shorten treatment duration.

@en

P1433

Q35127770-072FFDF8-642A-4DDB-B91D-27E8C770AEF1

P1476

Q35127770-56B080B1-7ACB-470A-9E7A-26C1B5C34646

P2093

Q35127770-3EDFB1AE-9FFE-4A2B-B2EF-B8CDE045C281

Q35127770-44A48CBE-AFC8-48C6-B509-5CBC5349036E

Q35127770-64D0B140-2722-4381-9A91-B1B0BE703039

Q35127770-96C741C7-FBE1-4ADC-8E5D-1B993392426A

Q35127770-BE1E5220-5361-48EA-8592-E1AECFDBDA0F

P2860

Q35127770-092FA1E7-10B6-4522-92B8-90AEBB46485E

Q35127770-144393BB-8B5E-47A9-9B3D-F99DAA1753FC

Q35127770-2E412F69-9586-4323-969E-F74768FB9FE5

Q35127770-5193D323-1F64-48C2-9C48-A00967577617

Q35127770-5AFCD081-F77A-4CA9-97C3-1019005C35F7

Q35127770-704D8389-F908-4B95-BED1-C4C4BC569BA0

Q35127770-782726E1-2428-4EB3-976C-F952C2BF1ADE

Q35127770-808F2553-1C28-4962-9312-A24D917515CB

Q35127770-87B9FDAD-FC09-4BD2-81C7-97644EE0EC07

Q35127770-8B797445-201E-4A80-AFB4-ED02F6C00D60

P304

Q35127770-86267290-1BA6-433F-A486-B8A488918ABF

P31

Q35127770-8CC899B3-6901-42BD-BDF8-442F3036F3BF

P356

Q35127770-12348F2A-538C-4A3D-962A-24F5EF6AB699

P407

Q35127770-9619AE5C-C574-40DE-BC42-A14030997E9A

P433

Q35127770-2D7D6CDC-460E-4AE3-9018-FC322DED9A98

P478

Q35127770-70993E6B-86CD-4117-B6A3-3B9EEBA4C3BA

P50

Q35127770-9648815F-0D7F-4665-BDF6-81442931D0BE

P577

Q35127770-40D06D7F-08DA-4AA6-8510-6133DB0D469C

P5875

Q35127770-54303CCF-B80E-440F-AA13-1967CA46A317

P698

Q35127770-8506B9FC-C377-44A0-A4BD-2B96AD0EC7AE

P921

Q35127770-3ABB1928-F051-458C-8A17-5CCF56211847

Q35127770-729C6BBF-AB2B-4E48-8EE6-CBF40463DAD9

P932

Q35127770-8392C853-AFAD-4F71-AF58-9126BDB14459

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Combinations of R207910 with d ...... to shorten treatment duration.

@en

P2093

Aurélie Chauffour

http://www.w3.org/2001/XMLSchema#string

Chantal Truffot-Pernot

http://www.w3.org/2001/XMLSchema#string

Koen Andries

http://www.w3.org/2001/XMLSchema#string

Nacer Lounis

http://www.w3.org/2001/XMLSchema#string

Vincent Jarlier

http://www.w3.org/2001/XMLSchema#string

P2860

Gatifloxacin and ethionamide as the foundation for therapy of tuberculosis

The curious characteristics of pyrazinamide: a review

Activities of pefloxacin and ofloxacin against mycobacteria: in vitro and mouse experiments

Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice

In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis

In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis.

Which aminoglycoside or fluoroquinolone is more active against Mycobacterium tuberculosis in mice?

A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis

The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis.

Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis.

P304

3543-3547

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.00766-06

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

50

http://www.w3.org/2001/XMLSchema#string

P50

Nicolas Veziris

P577

2006-09-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6836428

http://www.w3.org/2001/XMLSchema#string

P698

16954317

http://www.w3.org/2001/XMLSchema#string

P921

Akafuba bulwadde

multiple drug resistance

P932

1635167

http://www.w3.org/2001/XMLSchema#string